Physician profile
Wayne Warren
NPI 1447220496
$126,785.42
in general payments reported to CMS, 2019-2025
27 companies · $8,537 in 2025
The $8,537 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $16K · 2021: $13K · 2022: $6,939 · 2023: $23K · 2024: $20K · 2025: $8,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $5,299 · Food and Beverage: $3,724 · Consulting Fee: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,100.00 |
| Travel and Lodging | $5,299.12 |
| Food and Beverage | $3,723.69 |
| Consulting Fee | $1,557.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91,532.09 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $17,248.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $7,280.47 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $2,098.56 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $1,499.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,272.22 | 2019-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $1,095.85 | 2019-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $889.71 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $583.67 | 2019-2023 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $463.43 | 2019-2023 | |
| Corcept Therapeutics | $424.58 | 2019-2024 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $363.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $332.52 | 2019-2023 | Steglatro, Steglujan, Segluromet |
| Ironwood Pharmaceuticals, INC | $295.33 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.71 | 2022-2023 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $182.18 | 2019-2021 | |
| Abbvie INC. | $173.66 | 2021 | |
| Allergan, INC. | $157.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.84 | 2022 | |
| Pfizer INC. | $125.00 | 2019 | |
| Dexcom, INC. | $117.61 | 2022-2023 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $82.86 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $75.97 | 2023 | Evkeeza |
| Optinose US, INC. | $47.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.78 | 2020-2021 | |
| Genentech USA, INC. | $32.81 | 2019 | |
| Horizon Therapeutics Plc | $24.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.